Unlike PD‐1 antibodies, which act only on T‐cell immune checkpoints, iRGD NPs@si‐SOX9/CL silence the SOX9/TIMP1/FAK/PI3K axis, relieve immunosuppression, and simultaneously induce immunogenic tumor cell death, activating both DCs and CD8+ T cells for dual immune regulation.[53, 54] Compared with small‐molecule inhibitors, siRNA nanodelivery offers potent and specific gene silencing with higher efficiency and selectivity. Here, CD8A is linked to neoplasm.